Regnase-1 调控肺 2 型固有淋巴样细胞的促纤维化功能
该研究在小鼠模型中通过竞争性骨髓移植发现 Regnase-1 缺失导致肺 ILC2 自发增殖活化并上调纤维化相关基因,补充缺失 ILC2 可加重博来霉素诱导的肺纤维化。Regnase-1 抑制 Gata3 和 Egr1 mRNA,且 IPF 患者外周血 ILC2>1500 cells·mL-1 者预后更差,提示 Regnase-1 可能为 IPF 治疗新靶点。
要点
- Regnase-1 缺失使小鼠肺 ILC2 自发增殖活化并高表达纤维化相关基因。
- 补充 Regnase-1 缺失 ILC2 可加重博来霉素诱导的小鼠肺纤维化。
- IPF 患者外周血 ILC2>1500 cells·mL-1 者预后更差。
核心结论
- Regnase-1 是小鼠和人类 ILC2 促纤维化功能的关键转录后调控因子,可能成为 IPF 的新治疗靶点。
研究设计与样本
- 采用竞争性骨髓移植小鼠模型分析 Regnase-1 依赖的肺免疫细胞类型变化。
- 通过转录组分析和博来霉素诱导肺纤维化小鼠模型研究 ILC2 中 Regnase-1 与人类疾病的关联。
- 使用患者来源细胞评估 ILC2 中 Regnase-1 的临床意义。
主要发现
- Regnase-1 缺失导致小鼠肺 ILC2 自发增殖和活化。
- Regnase-1 缺失 ILC2 中肺纤维化相关基因较野生型高度上调。
- 补充 Regnase-1 缺失 ILC2 加重博来霉素诱导的小鼠肺纤维化。
- Regnase-1 抑制编码转录因子 Gata3 和 Egr1 的 mRNA。
- 支气管肺泡灌洗液中 ILC2 的 Regnase-1 蛋白水平与 ILC2 群体数量呈负相关。
关键数值与推荐
- IPF 患者外周血 ILC2>1500 cells·mL-1 者预后差于 ILC2 较低者。
临床怎么用
- IPF 患者外周血 ILC2>1500 cells·mL-1 可能提示预后较差。
- Regnase-1 通路可能作为 IPF 未来治疗干预的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Regnase-1 is an RNase critical for post-transcriptional control of pulmonary immune homeostasis in mice by degrading immune-related mRNAs. However, little is known about the cell types Regnase-1 controls in the lung, and its relevance to human pulmonary diseases.Regnase-1-dependent changes in lung immune cell types were examined by a competitive bone marrow transfer mouse model, and group 2 innate lymphoid cells (ILC2s) were identified. Then the associations between Regnase-1 in ILC2s and human diseases were investigated by transcriptome analysis and a bleomycin-induced pulmonary fibrosis mouse model. The clinical significance of Regnase-1 in ILC2s was further assessed using patient-derived cells.Regnase-1-deficiency resulted in the spontaneous proliferation and activation of ILC2s in the lung. Intriguingly, genes associated with pulmonary fibrosis were highly upregulated in Regnase-1-deficient ILC2s compared with wild-type, and supplementation of Regnase-1-deficient ILC2s augmented bleomycin-induced pulmonary fibrosis in mice. Regnase-1 suppresses mRNAs encoding transcription factors Gata3 and Egr1, which are potent to regulate fibrosis-associated genes. Clinically, Regnase-1 protein levels in ILC2 negatively correlated with the ILC2 population in bronchoalveolar lavage fluid. Furthermore, idiopathic pulmonary fibrosis (IPF) patients with ILC2s >1500 cells·mL-1 peripheral blood exhibited poorer prognosis than patients with lower numbers, implying the contribution of Regnase-1 in ILC2s for the progression of IPF.Collectively, Regnase-1 was identified as a critical post-transcriptional regulator of the profibrotic function of ILC2s both in mouse and human, suggesting that Regnase-1 may be a novel therapeutic target for IPF.
引用
- Nakatsuka Y, Yaku A, Handa T, et al. Profibrotic function of pulmonary group 2 innate lymphoid cells is controlled by regnase-1. Eur Respir J. 2021. PMID: 32978308. doi:10.1183/13993003.00018-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。